Introduction
Gastrointestinal stromal tumour has an estimated incidence in the USA of about 3000-4000 cases per year. 1, 2 It typically arises in the stomach or small intestine, but can also occur occasionally in the rectum and rarely in the oesophagus or colon. About 85% of such tumours contain an activating mutation in the KIT proto-oncogene, whereas 3-5% can have a mutation in PDGFRα, the gene encoding platelet-derived growth factor receptor α (PDGFRα). [3] [4] [5] [6] [7] The mainstay of treatment for localised, primary gastrointestinal stromal tumour has been surgical resection. Postoperative adjuvant chemotherapy has not generally been recommended because conventional cytotoxic agents are ineff ective against this tumour. 8 Unfortunately, the results of surgery alone have been inadequate, with up to 50% of patients developing tumour recurrence within 5 years and eventually dying from the disease. 9 , 10 The most frequent sites of initial tumour recurrence are the peritoneal surface and the liver. Imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland) is an oral agent that is a selective molecular inhibitor of the KIT, PDGFRα, ABL, and BCR-ABL tyrosine kinases. Imatinib was fi rst used for chronic myelogenous leukaemia, proving to be safe and achieving a complete haematological response in nearly all patients by inhibition of the BCR-ABL oncoprotein. 11 In 2000, imatinib was shown to be eff ective against metastatic gastrointestinal stromal tumour in the initial patient tested, 12 and effi cacy was then confi rmed in phase II 13, 14 and phase III trials in metastatic disease. 15, 16 In view of the activity of imatinib, the proclivity for tumour recurrence after resection, and the scarcity of eff ective conventional chemotherapeutic agents, there was substantial rationale for testing the benefi t of adjuvant imatinib in gastrointestinal stromal tumour.
Summary
Background Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-derived growth factor receptor α proteins, and is eff ective in fi rst-line treatment of metastatic gastrointestinal stromal tumour. We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour.
Methods
We undertook a randomised phase III, double-blind, placebo-controlled, multicentre trial. Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry. Patients were randomly assigned, by a stratifi ed biased coin design, to imatinib 400 mg (n=359) or to placebo (n=354) daily for 1 year after surgical resection. Patients and investigators were blinded to the treatment group. Patients assigned to placebo were eligible to crossover to imatinib treatment in the event of tumour recurrence. The primary endpoint was recurrence-free survival, and analysis was by intention to treat. Accrual was stopped early because the trial results crossed the interim analysis effi cacy boundary for recurrence-free survival. This study is registered with ClinicalTrials.gov, number NCT00041197. Interpretation Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.
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We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo in patients who underwent resection of localised, primary gastrointestinal stromal tumour.
Methods

Patients
We undertook a randomised phase III, double-blind, placebo-controlled, multicentre trial between July 1, 2002, and April 18, 2007 , in 230 institutions in USA and Canada. Patients were eligible for inclusion if they had a histological diagnosis of localised, primary gastrointestinal stromal tumour measuring at least 3 cm that expressed the KIT protein (CD117) by immunohistochemistry with the Dako antibody (DakoCytomation, Copenhagen, Denmark). The local institutional pathologist measured the size of the tumour, either before or after formalin fi xation. Two pathologists undertook retrospective central pathological review to confi rm the diagnosis. Patients were to be registered within 70 days after complete gross tumour resection (irrespective of microscopic margins) and start treatment by 84 days. The technique of resection was at the discretion of the individual surgeon.
Patients were at least 18 years of age with an Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 2 or less. Within 28 days before trial registration, patients must have been deemed free of tumour by postoperative imaging that included a baseline chest radiograph (or chest CT) and a postoperative abdomen and pelvis CT scan with intravenous and oral contrast, or MRI with intravenous contrast. Additional inclusion criteria were adequate renal, haematological, and hepatic function, and a negative serum pregnancy test when applicable. Previous imatinib use or chemotherapy, radiation therapy, or investigational treatment after surgery was not allowed. Also excluded were patients with an active infection requiring antibiotics within 14 days before registration, women who were breastfeeding, patients with New York Heart Association class 3 or 4 cardiac disease, and patients taking full dose warfarin.
The study was approved by the institutional review board of each participating institution, and we obtained written informed consent from all patients.
Study design and procedures
Patients were randomly assigned, in a double-blind manner, to receive 1 year of adjuvant imatinib (Novartis Pharmaceuticals, Basel, Switzerland) at a dose of 400 mg per day or 1 year of placebo. Patients were assigned to take four capsules of 100 mg imatinib or placebo once a day with food. Imatinib and placebo capsules looked alike. We assessed patients at weeks 1, 2, 4, 6, 8, 12, 16, 20 , and 24, then every 3 months until year 2, and then every 6 months until year 5 with physical examination; complete blood count with diff erential count, creatinine, bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase; and assessment of adverse events. We graded toxic eff ects with the National Cancer Institute common terminology criteria for adverse events (version 3.0). 17 Attribution was recorded as defi nite, probable, possible, unlikely, or unrelated to therapy. Dose modifi cations were made for grade 3 and 4 events (excluding anaemias) that were thought to be at least possibly related to treatment. Patients kept a diary to record dose administration and adverse events. CT scans with intravenous and oral contrast (or MRI with intravenous contrast) of the abdomen and pelvis were done every 3 months for the fi rst 2 years and then every 6 months for the next 3 years. At the time of reported tumour recurrence, the treatment group was unblinded after central review. A biopsy sample was mandatory and taken when medically feasible. Patients were not allowed to crossover before an observed recurrence. Patients who were unblinded for tumour recurrence were eligible for imatinib 400 mg per day if they had either been assigned to the imatinib group and already completed study therapy or assigned to the placebo group. Imatinib 800 mg per day could be prescribed if the patient was actively taking imatinib during recurrence.
Statistical analysis
The original primary endpoint was overall survival and we planned an accrual of 380 patients over 3·8 years with a minimum follow-up of 3 years. At a 0·05 one-sided level of signifi cance, the log-rank test would have had 90% power to detect a minimum hazard ratio (HR) of 0·65, assuming exponential decay in both groups and uniform censoring. 6 months before the fi rst planned effi cacy interim analysis, the primary endpoint was changed to recurrence-free survival on the basis of discussions with Cancer Therapy Evaluation Program (CTEP) and the US Food and Drug Administration (FDA). The trial was designed at the end of 2000, when fewer than 150 patients with metastatic gastrointestinal stromal tumour had been treated worldwide. During the present trial, it became clear that the actual event (death) rate would be substantially lower than the putative event rate that was specifi ed in the original statistical design because of the effi cacy of imatinib in recurrent gastrointestinal stromal tumour and the crossover design that allowed patients who progressed on placebo to receive imatinib. Consequently, the study was vastly underpowered to show a diff erence in overall survival between taking imatinib immediately after surgery versus waiting until recurrence occurred.
In the revised statistical design, the putative median recurrence-free survival for the placebo group was assumed to be 3·5 years on the basis of historical data. From the time of the amendment, the intent was to accrue 600 more patients over 2·5 years (to reach a total of 803), with a minimum follow-up of 3 years. This number would yield 90% power, at a 0·025 one-sided signifi cance level, to detect a 40% improvement in recurrence-free survival in the imatinib group, corresponding to a median recurrence-free survival of 4·9 years for the imatinib group and an HR of 0·71.
Interim analyses for superiority and futility were scheduled every 6 months beginning in December, 2005. We used a truncated O'Brien-Fleming bound to monitor treatment effi cacy. 18 Futility was monitored with a 0·0025 fi xed level of signifi cance at every interim analysis. This study was monitored by a data monitoring committee that was approved by CTEP and independent of the study sponsor (Novartis).
Patients were randomly assigned at the central offi ce of the American College of Surgeons Oncology Group (ACOSOG) via a computer programme with a stratifi ed biased coin design, with the objective of equal allocation to each group, and stratifi ed by tumour size (≥3-<6 cm, ≥6-<10 cm, or ≥10 cm). Patients and investigators were blinded to the group that the patient was assigned. 60 patients were misrandomised because of a programming error that assigned them to the placebo group. Patients, physicians, institutional review boards, and health authorities were notifi ed of the error and the patients were removed from the study. No data were collected for these patients after their removal from the study, resulting in no follow-up information for these patients.
Recurrence-free survival was defi ned as the time from patient registration to the development of tumour recurrence or death from any cause. Overall survival was defi ned as the time from patient registration to death from any cause. Patients who were alive and free of recurrent disease on April 12, 2007, were censored for overall survival and recurrence-free survival. Intention-to-treat analyses were done for both recurrence-free and overall survival (ie, we analysed patients by randomised group). Both endpoints were estimated with the Kaplan-Meier method. We analysed diff erences in recurrence-free and overall survival between the groups with a one-sided log-rank test stratifi ed by tumour size. HRs and 95% CIs were reported on the basis of a Cox proportion hazards regression model, which was also stratifi ed by tumour size for recurrence-free survival. On the basis of the recommendation of the ACOSOG data and safety monitoring committee, accrual to the study was stopped on April 12, 2007 , and the National Cancer Institute issued a press release of the preliminary fi ndings that day because the trial results crossed the interim analysis effi cacy boundary for recurrence-free survival. The fi nal analysis includes all data collected through April 12, 2007. This study is registered with ClinicalTrials.gov, number NCT00041197.
Role of the funding source
Employees of the study sponsor provided input regarding the study design, but did not participate in the collection, analysis, or interpretation of the data. Data were collected at the local institution and transferred electronically to the ACOSOG central database. The database was audited and updated by members of the Duke Clinical Research Institute, which received funding from the study sponsor. The results were analysed by the principal academic investigators. KVB and KO had full access to all the data in the study. This article was written by the lead author and reviewed by all authors, and was submitted to the sponsor for comments. RPD, KVB, and KO had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. The intention-to-treat analysis consisted of 713 patients. 60 of the 778 patients were excluded from the study because of a randomisation error and another fi ve were excluded because they were registered after the study closure date. The inten tion-to-treat population included 65 (9%) patients who did not meet all eligibility requirements (fi gure 1). We under took retrospective central pathology review in 631 (89%) patients, of whom 16 (3%) had another type of sarcoma (ten in imatinib group, six in placebo group). The other reasons for ineligibility were improper timing of baseline tests (laboratory or radiological) or surgery (eight in imatinib group, 18 in placebo group), incomplete baseline laboratory tests (fi ve in imatinib group, one in placebo group), incomplete baseline radiological imaging (four in imatinib group, six in placebo group), no pathological review (one in each group), presence of metastatic disease (one in each group), additional primary cancer (one in imatinib group), inadequate margins (one in imatinib group), and one patient in the imatinib group withdrew consent before any treatement. Clinicopathological features were similar between the study groups (table 1) .
Results
Treatment was stopped prematurely in 184 (26%) patients (fi gure 1). Discontinuation was most likely due to adverse events in the imatinib group (p<0·0001) and to tumour recurrence in the placebo group (p<0·0001). A dose reduction or interruption, or both, occurred for By the fi nal analysis of recurrence-free survival, 30 (8%) patients in the imatinib group and 70 (20%) in the placebo group had had events. With a median follow-up for surviving patients of 19·7 months (minimum-maximum 0-56·4), the estimated 1-year recurrence-free survival was 98% (95% CI 96-100) in the imatinib group versus 83% (78-88) in the placebo group (fi gure 2). The overall hazard ratio was 0·35 (0·22-0·53; p<0·0001). Although the trial was not designed to assess patient subsets, we analysed the eff ect of tumour size (the stratifi cation factor) and noted that recurrence-free survival was longer in the imatinib group than in the placebo group in each size category (fi gure 3). Five (1%) patients died in the imatinib group, all from causes unrelated to gastrointestinal stromal tumour. Eight (2%) deaths arose in the placebo group, fi ve of which were related to the tumour. At this time, there is no diff erence in overall survival (HR 0·66 [95% CI 0·22-2·03]; fi gure 4).
Discussion
Our results show that assignment to 1 year of adjuvant imatinib improved recurrence-free survival after the complete resection of primary gastrointestinal stromal tumour compared with placebo. Additionally, adjuvant imatinib was safe and well tolerated. The adverse event rate was low and consistent with imatinib use in chronic myelogenous leukaemia and metastatic gastrointestinal stromal tumour.
11, 13 We did not record signifi cant cardiac toxic eff ects that were noted by one group, 19 but refuted by others. 20 We chose to stratify patients on the basis of tumour size only. Mitotic rate and tumour site have also been reported to have prognostic importance in retrospective studies of primary gastrointestinal stromal tumour. Notably, none of these tumour features has been validated prospectively. Furthermore, the method of determining mitotic rate has not been standardised, and the reproducibility of measurements by diff erent pathologists (especially in a large, multicentre trial such as this study) has not been proven. Patients in the placebo group in this study provide a large prospective cohort of patients with primary gastrointestinal stromal tumour in which to identify risk factors for recurrence. This study also provides a large prospective assessment of recurrence with serial radiological imaging. Additional ad-hoc analyses related to risk factors for tumour recurrence will be forthcoming since central pathological and molecular analyses are underway. During the year of assigned study therapy, there were 41 recurrences in the placebo group compared with only one in the imatinib group. Recurrence-free survival was increased in each of the three size categories on retrospective analysis. Adjuvant therapy is especially relevant for high-risk patients (eg, those with tumour size 10 cm or more, or high mitotic rate), who can have a greater than 50% chance of recurrence at 2 years in the absence of adjuvant therapy (fi gure 3C). Notably, the rate of recurrence in the imatinib group (fi gure 2) seems to increase after about 18 months from surgery (ie, 6 months after the completion of study therapy). This fi nding is consistent with a trial in metastatic gastrointestinal stromal tumour in which patients receiving imatinib with responding or stable disease developed tumour progression at a median of 6 months after randomisation to discontinue therapy. 21 In metastatic gastrointestinal stromal tumour, imatinib achieves a partial response or stable disease in roughly 80% of patients, and a median survival of nearly 60 months (table 4) . [13] [14] [15] [16] Tumour mutation status predicts response to imatinib and survival. In a combined analysis of 1640 patients with metastatic gastro intestinal stromal tumour treated in two phase III trials, patients with KIT exon 11 mutations had the longest progression-free survival, those with a KIT exon 9 mutation had the worst outcome, and those without a KIT or PDGFRα mutation had an intermediate course. 22 Mutation studies are in progress in tumour specimens from this study.
Acquired resistance is a frequent event in patients with metastatic gastrointestinal stromal tumour who initially respond to imatinib. Tumour progression occurs at a median of 18-24 months, 15, 16 commonly from the development of a secondary mutation in the KIT gene. [23] [24] [25] Once clinical progression develops, increased doses of imatinib or sunitinib-a multitarget tyrosine kinase inhibitor (Sutent, Pfi zer, New York, NY, USA)-can restore tumour control in some patients, at least temporarily. 26, 27 At present there are no other FDA approved agents for metastatic gastrointestinal stromal tumour. Thus, the possibility to delay or prevent recurrence with adjuvant treatment is crucial since acquired resistance to tyrosine kinase inhibitors eventually occurs in most patients with measurable metastatic tumour. How cumulative exposure to imatinib (ie, in the adjuvant and metastatic settings combined) aff ects the development of imatinib resistance is unknown.
That overall survival between the study groups is similar is not surprising in view of the fairly short follow-up time and the crossover design of the study, which allowed patients assigned to the placebo group to receive imatinib on tumour recurrence. Although imatinib is rarely curative in metastatic gastrointestinal stromal tumour, 15, 16 it could eradicate residual microscopic disease in some patients after the removal of the primary tumour. Longer patient follow-up is necessary to establish whether adjuvant imatinib increases the cure rate of surgery alone for localised, primary gastrointestinal stromal tumour. Quality-of-life instruments were not used in this study. The advantage of improved recurrence-free survival by taking adjuvant imatinib has to be weighed against the potential toxic eff ects of the drug, even though it seems to be generally well tolerated.
In this study we excluded paediatric patients and those with gastrointestinal stromal tumours who did not have KIT staining by immunohistochemistry. Our fi ndings are probably not applicable to paediatric patients with such tumours that typically lack KIT or PDGFRα mutations and seem to be more responsive to sunitinib 28, 29 Our results might be relevant to the 4% of gastrointestinal stromal tumours that lack KIT expression, which often contain a KIT or PDGFRα mutation and can respond to imatinib. 30 Patients with specifi c mutations (ie, PDGFRα exon 18 D842V) that are known to be insensitive to imatinib in vitro and in metastatic gastrointestinal stromal tumour might not benefi t from adjuvant imatinib.
We tested only the starting dose of 400 mg per day in this study. The recent meta-analysis of the two phase III studies in metastatic gastrointestinal stromal tumour showed that 800 mg compared with 400 mg per day did not change overall survival but slightly improved progression-free survival at 3 years (34% vs 30%). 22 In particular, patients with KIT exon 9 mutations who were given the 800 mg dose had greater progression-free survival than did those given the 400 mg dose. Further studies will be needed to establish whether doses greater than 400 mg per day should be used in the adjuvant setting.
With the advent of tyrosine kinase inhibitors, eff ective agents against gastrointestinal stromal tumour now exist. In this phase III adjuvant trial of targeted therapy after the resection of localised, primary gastrointestinal stromal tumour, our fi ndings have shown that imatinib increases recurrence-free survival. Our fi ndings will aff ect the management of patients with primary gastrointestinal stromal tumour and could have relevance to the adjuvant use of other molecular agents for cancer.
